Free Trial

InspireMD Q2 2024 Earnings Report

InspireMD logo
$2.66 -0.04 (-1.30%)
As of 11:56 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

InspireMD EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.19
Beat/Miss
Missed by -$0.03
One Year Ago EPS
-$0.24

InspireMD Revenue Results

Actual Revenue
$1.74 million
Expected Revenue
$1.74 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

InspireMD Announcement Details

Quarter
Q2 2024
Time
Before Market Opens

Conference Call Resources

Conference Call Audio

Remove Ads

InspireMD Earnings Headlines

The unusual signal flashing green again
Something fascinating happened in April... While a lot of Wall Street institutions were opening new positions in a falling stock, something different showed up on my screen. A special set of candles had just turned green - signaling the kind of momentum surge I'd seen only a handful of times before. What happened next? The stock soared 45% on the underlying stock in just a few weeks and 227% for anyone who traded the options. Naturally, there would have been smaller wins and those that would not have worked out, but this wasn't some penny stock or crypto play… It was ARM Holdings - a major semiconductor player that had just shed 9% of its value.
InspireMD reports Q4 EPS (19c) vs (16c) last year
See More InspireMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InspireMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InspireMD and other key companies, straight to your email.

About InspireMD

InspireMD (NYSE:NSPR), a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

View InspireMD Profile

More Earnings Resources from MarketBeat